Coming off Ozempic: what the evidence says about stopping GLP-1s
Quick answer
Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al. withdrawal trial. The creator's checklist of lifestyle stabilization, metabolic bloodwork, and supplement support before stopping is clinically reasonable as a framework, but the supporting evidence for supplements like berberine preventing post-GLP-1 regain specifically is not established in controlled trials. Patients considering discontinuation should have a documented plan with their prescribing clinician, not derive one from social media content.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @breannekallonen actually say?
The creator, identifying as a functional medicine practitioner in Ontario, laid out a pre-discontinuation checklist for patients coming off semaglutide. The list covers nutrition habits (fiber and protein intake), exercise consistency, supplement use (psyllium fiber and berberine), and bloodwork including HbA1c, fasting insulin, hormones, cortisol, and thyroid markers. She frames semaglutide as "a tool" and focuses on whether lifestyle habits are stable enough to sustain results without the medication. She also flags insulin resistance as the root driver for many patients with resistant weight loss, and recommends berberine for those with strong genetic predisposition to insulin resistance or pre-diabetes.
The tone is measured. She explicitly says staying on GLP-1s long-term is fine if that's what a patient and their physician decide. That kind of nuance is rare in this content category.
Does the science back this up?
Mostly, yes, with some important caveats. The core concern, that weight regain after stopping semaglutide is significant and tied to lifestyle readiness, is well-documented. The supplement recommendations are where things get shakier.
On regain: a 2022 trial by Wilding et al. in Diabetes, Obesity and Metabolism found that participants regained roughly two-thirds of their lost weight within one year of stopping semaglutide, and appetite and hunger markers returned to near-baseline. This is the single most important data point anyone considering stopping GLP-1s should know. Lifestyle scaffolding matters, but it may not fully compensate for the appetite-suppressing pharmacology the drug was providing.
On psyllium fiber for appetite and blood sugar: solid ground here. A 2016 meta-analysis by Gibb et al. in the American Journal of Clinical Nutrition confirmed psyllium supplementation improves postprandial glucose and insulin response. The appetite effect is real but modest.
On berberine for insulin resistance: the evidence is promising but not definitive. A 2012 meta-analysis by Dong et al. in Evidence-Based Complementary and Alternative Medicine showed berberine reduced fasting glucose comparably to metformin in some populations. However, effect sizes vary widely, bioavailability is poor, and it is not FDA-approved for any indication. Calling it a supplement alternative for people with genetic insulin resistance risk is a stretch without individualized clinical assessment.
What did they get wrong (or right)?
Credit where it's due: framing bloodwork (HbA1c, fasting insulin, thyroid, cortisol) as a pre-discontinuation checkpoint is genuinely good practice. Most clinicians don't do this systematically, and it reflects real clinical thinking about why weight returns after stopping GLP-1s.
The muscle mass point also holds. She references maintaining "sustained lean muscle mass" into older age as a quality-of-life marker. This tracks with data from Bhasin et al. and other sarcopenia literature linking lean mass preservation to functional longevity.
What's weaker: the claim that when these factors are "dialed in, weight loss is maintained" is stated with more confidence than the evidence supports. There is no published RCT showing that a fiber-berberine-protein-exercise protocol reliably prevents regain after GLP-1 discontinuation. That may be her clinical observation, but it shouldn't be presented as an established finding.
The phrase "insulin resistance" is used loosely to describe a broad population. Not every person on semaglutide has clinically significant insulin resistance, and recommending berberine without confirmed metabolic indication is premature.
What should you actually know?
If you are thinking about stopping semaglutide, the regain data should be your first read, not a TikTok checklist. The Wilding 2022 study is public and free to access. The biological drive to regain weight after stopping a GLP-1 agonist is not a willpower failure. It is pharmacology reversing.
The lifestyle habits this creator recommends, consistent protein, fiber intake, structured movement, good sleep, stress management, are legitimate health goals with independent benefits. They are not a guaranteed substitute for the medication's appetite and glycemic effects.
Berberine is not a regulated drug. It is not equivalent to metformin. It is not approved to treat insulin resistance or pre-diabetes. If your clinician is recommending it, ask them what specific bloodwork finding they are responding to and what the monitoring plan is.
The bloodwork panel she recommends is reasonable as a snapshot of metabolic health before discontinuing. But bloodwork alone does not predict whether you will maintain weight loss. Behavior over time does, and even strong behavior may not fully replace what a GLP-1 was doing physiologically.
Work with a licensed prescriber. Do not stop or reduce a GLP-1 medication based on a TikTok video, including this one.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Coming off Ozempic: what the evidence says about stopping GLP-1s, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al.
FormBlends verdict
Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al. withdrawal trial. The creator's checklist of lifestyle stabilization, metabolic bloodwork, and supplement support before stopping is clinically reasonable as a framework, but the supporting evidence for supplements like berberine preventing post-GLP-1 regain specifically is not established in controlled trials. Patients considering discontinuation should have a documented plan with their prescribing clinician, not derive one from social media content.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al. withdrawal trial. The creator's checklist of lifestyle stabilization, metabolic bloodwork, and supplement support before stopping is clinically reasonable as a framework, but the supporting evidence for supplements like berberine preventing post-GLP-1 regain specifically is not established in controlled trials. Patients considering discontinuation should have a documented plan with their prescribing clinician, not derive one from social media content.
- Wilding et al. (2022) found patients regained approximately two-thirds of weight within 12 months of stopping semaglutide, even with continued lifestyle support.
- Psyllium fiber supplementation has documented evidence for modest improvements in postprandial blood sugar and LDL cholesterol (Gibb et al., 2016, AJCN), making it a reasonable add-on but not a GLP-1 replacement.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Wilding et al. (2022) found patients regained approximately two-thirds of weight within 12 months of stopping semaglutide, even with continued lifestyle support.
- Psyllium fiber supplementation has documented evidence for modest improvements in postprandial blood sugar and LDL cholesterol (Gibb et al., 2016, AJCN), making it a reasonable add-on but not a GLP-1 replacement.
- Berberine is not FDA-approved for insulin resistance or pre-diabetes and should not be treated as an equivalent to metformin or a clinical substitute for GLP-1 therapy.
- A pre-discontinuation bloodwork panel covering HbA1c, fasting insulin, thyroid, and hormones is clinically sound practice and can identify metabolic factors that may increase regain risk.
- Lean muscle mass preservation through resistance or aerobic exercise has strong independent evidence for functional longevity, regardless of GLP-1 status (Cruz-Jentoft et al., 2019, Age and Ageing).
- No published RCT has demonstrated that a fiber-berberine-protein-exercise protocol reliably prevents weight regain after GLP-1 discontinuation; the creator's confidence here exceeds the available data.
- Any decision to stop or taper a GLP-1 medication should be made with the prescribing clinician, not based on a social media checklist, however well-intentioned.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Breanne Kallonen ND · TikTok creator
413.3K views on this video
If you are planning to come off ozempic here is what to consider #bloodwork #functionalmedicine #ontario #hairloss #pcos #hormones #doctorsoftiktok #ozempic #insulinresistance #bloodsugar
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Breanne Kallonen ND, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.